Clinical Trial Update: Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating fluorizoparib plus apatinib versus chemotherapy in HRD-positive/HER2-negative metastatic breast cancer; the study is currently active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Apatinib (apatinib)
• Fluorizoparib (fluorizoparib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING